Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at Oppenheimer

Astria Therapeutics (NASDAQ:ATXS) had its target price upped by investment analysts at Oppenheimer from $26.00 to $28.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective would suggest a potential upside of 163.90% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on ATXS. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. Finally, TD Cowen assumed coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Stock Performance

ATXS stock opened at $10.61 on Thursday. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The stock has a fifty day moving average of $11.46 and a 200-day moving average of $10.61. The company has a market capitalization of $598.67 million, a price-to-earnings ratio of -4.61 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Equities analysts predict that Astria Therapeutics will post -1.68 EPS for the current year.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares in the last quarter. American International Group Inc. grew its holdings in shares of Astria Therapeutics by 49.4% during the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after purchasing an additional 8,122 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics in the 1st quarter worth $200,000. Finally, Tidal Investments LLC purchased a new position in Astria Therapeutics in the 1st quarter worth $1,664,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.